Long-term thromboprophylaxis in practice: How can it be implemented?

Orthopedics

Volumn 23, Issue 6 SUPPL., 2000, Pages

  Nurmohamed, Michael T ^a,c   MacGillavry, Melvin R ^b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; CLINICAL PRACTICE; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG DOSAGE FORM; DRUG SAFETY; DRUG SELF ADMINISTRATION; HOSPITAL DISCHARGE; INCIDENCE; PATIENT MONITORING; PROPHYLAXIS; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SELF ADMINISTRATION; VENOUS THROMBOSIS;

EID: 0033916271     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Huber O, Bounameaux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge. Arch Surg. 1992; 127:310-313.
2. Scurr JH, Coleridge-Smith PD, Hasty JH, et al. Deep venous thrombosis: a continuing problem. Br Med J. 1988; 297:28.
3. Trowbridge A, Boese CK, Woodruff B, et al. Incidence of posthospitalization proximal deep vein thrombosis after total hip replacement arthroplasty. Clin Orthopaed. 1994; 299:203-208.
4. Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg. 1985; 72:105-108.
5. Tremain JD, Chroszy CH, Menking SA. Deep vein thrombosis in total hip arthroplasty patients. J Vasc Technol. 1992; 16:23-27.
6. Nurmohamed MT, Lems WF, Dijkmans BAC. Risk of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty. Is prolonged thromboprophylaxis warranted or dangerous? Ann Rheum Dis. 1999; 58:392-395.
7. Prevention of venous thromboembolism. International consensus statement (guidelines according to scientific evidence). Int Angiol. 1997; 16:3-38.
8. Clagett GP, Anderson FA Jr, Geerts W, et al. Prevention of venous thromboembolism. Fifth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 1998; 114(5 suppl):531S-560S.
9. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335:696-700.
10. Dahl OE, Andreassen G, Müller C, et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis and pulmonary embolism 35 days after hip replacement surgery. Thromb Haemost. 1995; 73:1094. Abstract.
11. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) study. Thromb Res. 1998; 89:281-287.
12. Planes A, Vochelle N, Darmon J-Y, et al. Risk of deep venous thrombosis after hospital discharge in patients undergoing total hip replacement. Double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996; 348:224-228.
13. Levine MN, Raskob G, Hirsh J. Risk of haemorrhage associated with long-term anticoagulant therapy. Drugs. 1985; 30:444-460.
14. Detournay B, Planes A, Vochelle N, Fagnani F. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics. 1998; 13(1 pt 1):81-89.
15. Sarasin FP, Bounameaux H. Cost-effectiveness of prophylactic anti-coagulation prolonged after hospital discharge following general surgery. Arch Surg. 1996; 131:694-697.
16. Sarasin FP, Bounameaux H. Antithrombotic strategy after total hip replacement. Arch Intern Med. 1996; 156:1661-1668.